Briacell Therapeutics Ev To Operating Cash Flow Over Time

BCTX Stock  USD 0.53  0  0.85%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Briacell Therapeutics Performance and Briacell Therapeutics Correlation.
  
EV To Operating Cash Flow is likely to rise to 0.04 in 2024.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Briacell Therapeutics. If investors know Briacell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Briacell Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.89)
Return On Assets
(1.26)
Return On Equity
(2.06)
The market value of Briacell Therapeutics is measured differently than its book value, which is the value of Briacell that is recorded on the company's balance sheet. Investors also form their own opinion of Briacell Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Briacell Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Briacell Therapeutics' market value can be influenced by many factors that don't directly affect Briacell Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Briacell Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Briacell Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Briacell Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Ev To Operating Cash Flow Analysis

Compare Briacell Therapeutics and related stocks such as X4 Pharmaceuticals, Terns Pharmaceuticals, and Day One Biopharmaceu Ev To Operating Cash Flow Over Time
Select Fundamental
Price To Sales RatioPtb Ratio
Days Sales OutstandingBook Value Per Share
Free Cash Flow YieldInvested Capital
Operating Cash Flow Per ShareAverage Payables
Stock Based Compensation To RevenueCapex To Depreciation
Pb RatioEv To Sales
Free Cash Flow Per ShareInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Sales General And Administrative To RevenueAverage Inventory
Research And Ddevelopement To RevenueCapex To Revenue
Cash Per SharePocfratio
Interest CoveragePayout Ratio
Capex To Operating Cash FlowPfcf Ratio
Days Payables OutstandingNet Current Asset Value
Income QualityTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Ev To Free Cash FlowIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareGraham Number
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D ADividend Yield
RoicPayables Turnover
RoeReturn On Tangible Assets
Earnings YieldReceivables Turnover
Short Term Coverage RatiosPrice Earnings Ratio
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioOperating Cash Flow Sales Ratio
Days Of Inventory OutstandingDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Capital EmployedFixed Asset Turnover
Return On AssetsAsset Turnover
Return On Equity
201020112012201320142015201620172018201920202021202220232024
XFOR(7.2628)(7.2628)(7.2628)(7.2628)(7.2628)(7.2628)(4.1764)1.37230.4027(0.4183)(1.5103)(0.2392)0.2622(1.1207)(1.18)
TERN(19.8283)(19.8283)(19.8283)(19.8283)(19.8283)(19.8283)(19.8283)(19.8283)(19.8283)(6.7833)(13.4213)(3.1309)(4.5773)(5.6855)(5.97)
DAWN(316)(316)(316)(316)(316)(316)(316)(316)(316)(316)(105)(15.6535)(12.0538)(6.3622)(6.68)
PDSB(140)(140)(140)(19.6796)(15.9793)1.0938(8.3681)(5.3366)0.7416(0.0409)(0.5784)(11.4195)(12.7253)(3.601)(3.78)
INZY(24.3231)(24.3231)(24.3231)(24.3231)(24.3231)(24.3231)(24.3231)(24.3231)(24.3231)(12.4555)(9.0081)(2.9224)(0.234)(3.2945)(3.46)
ELEV(49.5544)(49.5544)(49.5544)(49.5544)(49.5544)(49.5544)(49.5544)(49.5544)(49.5544)(49.5544)(15.6457)0.2183(0.0658)0.01460.0153
MREO(8.7844)(8.7844)(8.7844)(8.7844)(8.7844)(8.7844)(8.7844)(13.0427)(19.8335)(6.73)(42.4646)(146)(10.5316)(69.6512)(73.13)
HEPA(3.5 M)(3.5 M)(3.5 M)(9.1003)(10.9515)(1.2533)(1.0861)(2.6701)(0.143)0.2861.16180.34910.80850.04190.0439
HOOK(187)(187)(187)(187)(187)(187)(187)(187)(149)(49.8842)(3.9809)(0.3085)2.69180.59050.62

Briacell Therapeutics and related stocks such as X4 Pharmaceuticals, Terns Pharmaceuticals, and Day One Biopharmaceu Ev To Operating Cash Flow description

A valuation metric comparing the company's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows.

My Equities

My Current Equities and Potential Positions

Briacell Therapeutics Corp
BCTX
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationBritish Columbia; Canada
ExchangeNASDAQ Exchange
USD 0.5345

Additional Tools for Briacell Stock Analysis

When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.